http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
수술로 초치료한 병기 IB 1 자궁경부암 환자에 있어서 편평상피암과 선암의 예후 비교
임재윤,이기헌,송명섭,홍재식,성석주,김태진,임경택,김재욱,박종택 대한부인종양학회 2006 Journal of Gynecologic Oncology Vol.16 No.3
The objective of this study was to compare clinical and pathologic variables and prognosis of FIGO stage IB1 adenocarcinoma and squamous cell carcinoma of uterine cervix who were treated primarily by surgery. Methods From May 1982 to October 2000, 2209 patients with invasive cancer of the uterine cervix were diagnosed and treated at Cheil Hospital. A retrospective review was performed of 533 patients with stage IB1 squamous cell carcinoma (group A) and 84 with adenocarcinoma (group B) of cervix who treated primarily by type 3 hysterectomy and pelvic and paraaortic lymphadenectomy. Results Age, endometrial extension, lymph node metastasis and postoperative adjuvant therapy were not different between two group. There were more the lymphovascular space invasion in group A (136 patients ,25.5%) than group B (9 patients ,10.7%) (p < 0.0046). 5 year survival were 95.0% vs 93.8% for group A and group B ( P = 0.75 ). Using univariate analysis, pelvic node metastasis, paraaortic metastasis, postoperative adjuvant therapy were significant for survival. Multivariate analysis of 5 year survival revealed independent prognostic factor as postoperative adjuvant therapy. Conclusion Prognosis of FIGO stage IB1 cervical cancer patients who were treated by primarily by type 3 hysterectomy and pelvic and paraaortic lymphadenectomy between adenocarcinoma and squamous cell carcinoma was found to be same. 목적 : 본 연구는 수술로 초치료한 자궁경부암 Ib1 환자들을 대상으로 선암과 편평상피암의 임상병리학적 특성과 5년 생존율을 비교하기 위하여 시행되었다. 연구 방법 : 1982년 5월부터 2000년 10월까지 삼성제일병원 산부인과에서 자궁경부암으로 진단받은 2209예의 환자 중 533명의 Ib1 편평상피암과 84명의 선암 환자를 대상으로 하였다. 환자들의 임상 및 조직학적 양상에 관한 자료는 의무기록 및 본원에 등록 보관된 암 등록지를 조사, 분석하였으며, 치료 후 외래에서의 정기적인 관찰기록, 환자 또는 가족과의 전화연락 등을 종합하여 환자의 연령, 병리조직학적 분포, 림프 혈관 침윤(lymphovascular space invasion), 자궁내막으로의 침윤(endometrial extension), 골반 및 부대동맥 림프절 전이 등을 알아보고, 각 예후인자에 대한 5년 생존율을 비교 분석하였다. 결과 : 두 군간에 환자의 나이, 자궁내막으로의 침윤, 골반 림프절 전이, 부대동맥 림프절 전이 및 수술 후 추가 치료의 빈도는 차이가 없었다. 림프 혈관침윤은 편평상피암(25.5%)이 선암(10.7%)보다 많았다. 5년 생존율은 편평상피암이 95.0%, 선암이 93.8%였다.(P=0.75) 단변량 분석에서 골반 림프절 전이, 부대동맥 림프절 전이, 수술 후 추가 치료 여부가 생존율에 유의하게 영향을 미쳤고, 다변량 분석에서는 수술 후 추가 치료 여부만이 생존율에 유의한 영향을 미치는 예후인자였다. 결론 : 초치료로 광범위자궁적출술과 골반 및 부대동맥 림프절 절제술을 시행한 Ib1 자궁경부암 환자에 있어서 선암과 편평상피암의 예후는 같았다.
임재윤,남상천 충북대학교 건설기술연구소 1990 建設技術論文集 Vol.8 No.2
A method to create a load model of bus, which consists of several component loads, is composed of individual load model by load composition rate. This paper estimated load composition rate on the basic of coefficients, which were calculated by survey data, energy census, statistic data, a meteorological information and life information etc. The load composition rate, which was classed by group of load and season, applied substation in real power system. The result found load composition rate hourly, in particular, motor load of dynamic characteristic, which have a close relationship to load model, accounted for 70 percent of all hour at industrial load bus.
전력용 변압기의 유중가스 해석을 위한 지능형 진단 알고리즘 개발
임재윤,이대종,이종필,지평식,Lim, Jae-Yoon,Lee, Dae-Jong,Lee, Jong-Pil,Ji, Pyeong-Shik 한국조명전기설비학회 2007 조명·전기설비학회논문지 Vol.21 No.7
IEC code based decision nile have been widely applied to detect incipient faults in power transformers. However, this method has a drawback to achieve the diagnosis with accuracy without experienced experts. In order to resolve this problem, we propose an artificial diagnosis algorithm to detect faults of power transformers using Self-Organizing Feature Map(SOM). The proposed method has two stages such as model construction and diagnostic procedure. First, faulty model is constructed by feature maps obtained by unsupervised learning for training data. And then, diagnosis is performed by compare feature map with it obtained for test data. Also the proposed method usぉms the possibility and degree of aging as well as the fault occurred in transformer by clustering and distance measure schemes. To demonstrate the validity of proposed method, various experiments are unformed and their results are presented. 일반적으로 변압기의 고장진단을 위해 IEC 코드법이 사용되지만, 이 방법은 가스비율이 규정된 범위 내에 존재하지 않거나 경계조건에 있는 경우 숙련된 진단 전문가에게 의뢰하지 않고는 정확한 고장의 원인을 판정하는데 어려움이 있다. 이러한 문제점을 해결하기 위하여 본 논문에서는 SOM을 이용한 전력용 변압기의 고장진단 알고리즘을 제안한다. 제안된 방법은 훈련 데이터의 경쟁학습을 통하여 자기 구성 맵을 구축한 후, 실증 데이터를 구축된 맵에 적용하여 고장의 진단이 이루어진다. 또한 클러스터링 기법에 의해 구축된 정상/고장모델과 정상 데이터를 비교함으로써 고장의 추이 및 열화정도를 분석한다. 제안된 방법의 유용성을 보이기 위한 실험결과에서 기존의 방법들에 비해 향상된 진단결과를 보임을 확인할 수 있었다.
임재윤,조장호,이세준,이동기,윤동섭,조재용 대한암학회 2015 Cancer Research and Treatment Vol.47 No.2
Purpose The purpose of this study is to retrospectively compare the efficacy and tolerability betweenthree regimens for first-line chemotherapy—gemcitabine plus capecitabine (GEM-X),gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy (GEM)—in patients withadvanced pancreatic cancer. Materials and MethodsThere was a total of 127 patients who underwent chemotherapy for pancreatic cancerbetween January 2007 and November 2011 at our institution. Patients were treated witheither GEM (gemcitabine 1,000 mg/m2 on days 1, 8, and 15 every 4 weeks), GEM-T(gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks and erlotinib 100 mg daily), orGEM-X (gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks and capecitabine 850mg/m2 twice daily for 2 weeks followed by 1 week’s rest) as the first-line treatment. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and toxicitywere evaluated. ResultsThe patient population was divided into groups depending on their first-line treatment: GEM(n=47), GEM-T (n=44), and GEM-X (n=36). GEM-X significantly improved ORR (21.2% vs. 12.7% and 15.9%), PFS (8.9 vs. 5.2 and 3.9 months; p < 0.001), and OS (12.1 vs. 10.4and 9.9 months; p = 0.03) compared to GEM and GEM-T, respectively. There were higherincidences of some non-hematologic adverse events with GEM-X and GEM-T compared toGEM, but most were grade 1 or 2. ConclusionGEM-X presented better clinical efficacy and acceptable tolerability than GEM-T and GEMin advanced pancreatic cancers. It is worthy to further investigate which agent has a clinicaladvantage as a combination drug with gemcitabine in pancreatic cancer and to explore thepredictive markers leading to personalize anti-cancer treatment.